Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 1, 1998, Pages 55-60

  Vidal, Carmen ^a   García, Felipe ^a   Gatell, José María ^a,d   Leal, Manuel ^b   Clotet, Bonaventura ^c   Pumarola, Tomás ^a   Míro, José María ^a   Mallolas, José ^a   Ruiz, Lídia ^c   Cruceta, Anna ^a   Tortajada, Cecilia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiretroviral naive patients; Nucleoside reverse transcriptase inhibitors; Peak reduction; Predictive factors; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VIREMIA; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROBABILITY; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032168154     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199809010-00009     Document Type: Article

References (24)

1. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
2. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-45
3. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
4. Coombs RW, Todd JA, Herman SA, et al. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
6. Katlama C, Valantin MA, Calvez V, et al. ALTIS: a pilot open, study of d4T/3TC in antiretroviral naive and experienced patients. IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
7. Conway B, Montaner JSG, Raboud JM, et al. Immunological and virological effects of combination therapy with ZDV plus ddI or ddC. III Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
8. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
9. Rouleau D, Montaner JSG, Conway B, et al. Predictors of viral load response in a pilot-open label study of stavudine in combination with lamivudine. IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
10. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276:146-54.
11. Carpenter C, Feinberg M, Aubry W, et al. NIH draft report principles of therapy of HIV infection. http://www.healthcg.com/hiv/ nihreport/, 1997.
12. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9.
13. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
14. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
15. Ioannidis JP, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996;10:255-62.
16. Gatell JM, Leal M, Mallolas J, et al. A pilot case-control study of zidovudine compared to zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals. Antiviral Ther 1996;1:105-12.
17. Ruiz L, Romeu J, Ibáñez A, et al. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine. Antiviral Ther 1996;1:220-4.
18. - >500 cells/μL [abstract 565.]. IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
19. Katlama C, Valantin MA, Calvez V, et al. ALTIS: a pilot open study of d4T/3TC in antiretroviral naïve and experienced patients. IV Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
20. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-1.
21. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
22. St Clair MH, Hartigan PM, Andrews JC. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993;6:891-7.
23. Evans JS, Nims T, Cooley J, Et al Serum levels of viral burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997;175:795-800.
24. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996;347: 1569-70.